We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $43.10, moving -4.14% from the previous trading session. This change lagged the S&P 500's 0.59% loss on the day. Meanwhile, the Dow experienced a drop of 0.6%, and the technology-dominated Nasdaq saw a decrease of 0.65%.
Shares of the medical device manufacturer witnessed a loss of 12.56% over the previous month, trailing the performance of the Medical sector with its loss of 0.36%, and the S&P 500's loss of 1.37%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is predicted to post an EPS of $0.8, indicating a 6.67% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.28 billion, up 4.22% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.3 per share and revenue of $21.33 billion, which would represent changes of +7.84% and +6.28%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Boston Scientific is currently sporting a Zacks Rank of #5 (Strong Sell).
Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 13.62. This valuation marks a discount compared to its industry average Forward P/E of 20.81.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.76.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 94, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BSX in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX - Free Report) closed the most recent trading day at $43.10, moving -4.14% from the previous trading session. This change lagged the S&P 500's 0.59% loss on the day. Meanwhile, the Dow experienced a drop of 0.6%, and the technology-dominated Nasdaq saw a decrease of 0.65%.
Shares of the medical device manufacturer witnessed a loss of 12.56% over the previous month, trailing the performance of the Medical sector with its loss of 0.36%, and the S&P 500's loss of 1.37%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is predicted to post an EPS of $0.8, indicating a 6.67% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.28 billion, up 4.22% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.3 per share and revenue of $21.33 billion, which would represent changes of +7.84% and +6.28%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Boston Scientific is currently sporting a Zacks Rank of #5 (Strong Sell).
Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 13.62. This valuation marks a discount compared to its industry average Forward P/E of 20.81.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.76.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 94, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BSX in the coming trading sessions, be sure to utilize Zacks.com.